Melinda A. Biernacki

Oncology

825 Eastlake Ave E
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Herpes Simplex Virus Serostatus and 1-Year Mortality Among Allogeneic Hematopoietic Cell Transplant Recipients.

Herpes Simplex Virus Serostatus and 1-Year Mortality Among Allogeneic Hematopoietic Cell Transplant Recipients.

Journal: medRxiv : the preprint server for health sciences

Published: August 20, 2026

Incidence and Management of Early Breakthrough HSV Infection Among Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Incidence and Management of Early Breakthrough HSV Infection Among Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Journal: medRxiv : the preprint server for health sciences

Published: August 20, 2026

Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.

Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.

Journal: Blood advances

Published: March 02, 2026

Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.

Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.

Journal: Blood advances

Published: March 02, 2026

The TCXpress lane to T-cell receptor-engineered T cells.

The TCXpress lane to T-cell receptor-engineered T cells.

Journal: Blood advances

Published: February 24, 2026

The TCXpress lane to T-cell receptor-engineered T cells.

The TCXpress lane to T-cell receptor-engineered T cells.

Journal: Blood advances

Published: February 13, 2026

Plant-based whole-food diets are feasible during autologous stem cell transplantation and are associated with dose-dependent microbiome modulation: Results from a pilot clinical trial.

Plant-based whole-food diets are feasible during autologous stem cell transplantation and are associated with dose-dependent microbiome modulation: Results from a pilot clinical trial.

Journal: medRxiv : the preprint server for health sciences

Published: February 12, 2026

Capturing the Big Picture of HY Antigens and Transplantation Outcomes.

Capturing the Big Picture of HY Antigens and Transplantation Outcomes.

Journal: Transplantation and cellular therapy

Published: November 01, 2025

Optimizing post-transplantation cell therapies to enhance graft-versus-leukemia effects in hematological malignancies.

Optimizing post-transplantation cell therapies to enhance graft-versus-leukemia effects in hematological malignancies.

Journal: Current opinion in immunology

Published: August 28, 2025

Clinical trials, challenges, and changes in TCR-based therapeutics for hematologic malignancies.

Clinical trials, challenges, and changes in TCR-based therapeutics for hematologic malignancies.

Journal: Expert review of hematology

Published: December 12, 2024

Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report.

Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report.

Journal: EJHaem

Published: September 09, 2024

HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.

HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.

Journal: Blood

Published: January 29, 2024

Showing 1-12 of 25

Last Updated: 09/26/2026